Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773131 | 1.00 | CSNK1A1 (0.49) | CSNK1A1TYRO3DYRK1BTAAR1MTOR | |
| SCHEMBL7235096 | 0.85 | TAAR1 (0.49) | CSNK1A1TYRO3DYRK1BTAAR1MTOR | |
| SCHEMBL6002865 | 0.82 | CSNK1A1 (0.49) | CSNK1A1TYRO3DYRK1BTAAR1MTOR | |
| SCHEMBL9287236 | 0.80 | NISCH (0.64) | CSNK1A1TYRO3DYRK1BTAAR1MTOR | |
| SCHEMBL27838439 | 0.79 | TRPA1 (0.43) | TAAR1MTORADKNISCHTRPA1 | |
| SCHEMBL14886257 | 0.78 | NISCH (0.61) | CSNK1A1TYRO3DYRK1BTAAR1MTOR | |
| SCHEMBL9377527 | 0.78 | NISCH (0.50) | CSNK1A1TYRO3DYRK1BTAAR1MTOR | |
| SCHEMBL8536119 | 0.77 | TAAR1 (0.47) | TAAR1MTORADKNISCHALDH1A1 | |
| SCHEMBL1289114 | 0.76 | NISCH (0.53) | CSNK1A1TYRO3DYRK1BMTORADK | |
| SCHEMBL29985833 | 0.76 | NISCH (0.53) | CSNK1A1TYRO3DYRK1BMTORADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | claimed |
| CN-118290450-A | Europium-aluminum-containing lithium adsorbent precursor and preparation method thereof | 万华化学集团股份有限公司 | 2024-07-05 | — | — | CN | claimed |
| EP-4277592-A1 | TOPICAL COMPOSITION | Liliger Ltd (IL) | 2023-11-22 | — | — | EP | claimed |
| WO-2022153308-A1 | TOPICAL COMPOSITION | RICH PSC LTD. (IL) | 2022-07-21 | — | — | WO | claimed |
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | disclosed |
| CN-118290450-A | Europium-aluminum-containing lithium adsorbent precursor and preparation method thereof | 万华化学集团股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4277592-A1 | TOPICAL COMPOSITION | Liliger Ltd (IL) | 2023-11-22 | — | — | EP | disclosed |
| US-20230355500-A1 | TOPICAL COMPOSITION | LILIGER LTD (IL) | 2023-11-09 | — | — | US | disclosed |
| WO-2022153308-A1 | TOPICAL COMPOSITION | RICH PSC LTD. (IL) | 2022-07-21 | — | — | WO | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | CSNK1A1 2313/4885TYRO3 3028/4885DYRK1B 4348/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CSNK1A1 2313/4885TYRO3 3028/4885DYRK1B 4348/4885 |
| US-20230355500-A1 | TOPICAL COMPOSITION | NOS1, NOS3, NOS2 | CSNK1A1 968/4885TYRO3 1691/4885DYRK1B 2202/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CSNK1A1 2313/4885TYRO3 3028/4885DYRK1B 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.